Shengtao L. Zhou

Key Laboratory Of Birth Defects And Related Diseases Of Women And Children Of Ministry Of Education And State Key Laboratory Of Biotherapy
Chengdu, 610000, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 94 publications

Less is more: patients with cervical cancer benefit from de-escalated chemotherapy plus immuno-targeted therapies.

Less is more: patients with cervical cancer benefit from de-escalated chemotherapy plus immuno-targeted therapies.

Journal: Cancer biology & medicine
Published: June 24, 2026

Context dependency in cancer neuroscience.

Context dependency in cancer neuroscience.

Journal: Cancer cell
Published: May 07, 2026

An immunological panacea for cancer-related cachexia.

An immunological panacea for cancer-related cachexia.

Journal: Trends in cancer
Published: December 31, 2025

Charting the nerve-immune axis in endometriosis.

Charting the nerve-immune axis in endometriosis.

Journal: Trends in immunology
Published: September 30, 2025

Cadonilimab rechallenge in patients with recurrent or metastatic cervical cancer following prior PD-1/PD-L1 inhibitor failure: a retrospective multicenter study.

Cadonilimab rechallenge in patients with recurrent or metastatic cervical cancer following prior PD-1/PD-L1 inhibitor failure: a retrospective multicenter study.

Journal: Frontiers in immunology
Published: September 08, 2025

Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer.

Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer.

Journal: Cancer discovery
Published: July 28, 2025

Neoadjuvant therapy of iparomlimab and tuvonralimab combined with chemotherapy-extenuated for locally advanced cervical cancer (NICE-CC): an investigator-initiated, multicentre, open-label, phase II trial.

Neoadjuvant therapy of iparomlimab and tuvonralimab combined with chemotherapy-extenuated for locally advanced cervical cancer (NICE-CC): an investigator-initiated, multicentre, open-label, phase II trial.

Journal: Journal of gynecologic oncology
Published: July 28, 2025

Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma.

Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma.

Journal: Cancer discovery
Published: April 11, 2025

Clinical features and prognostic factors of ovarian cancer brain metastases from ovarian cancer: a retrospective multicenter study of 129 cases.

Clinical features and prognostic factors of ovarian cancer brain metastases from ovarian cancer: a retrospective multicenter study of 129 cases.

Journal: BMC cancer
Published: April 03, 2025

Spatiotemporal Immune Determinants of Response to Immune Rechallenge in Advanced Cervical Cancer.

Spatiotemporal Immune Determinants of Response to Immune Rechallenge in Advanced Cervical Cancer.

Journal: Cancer discovery
Published: March 18, 2025

Deciphering the "Rosetta Stone" of ovarian cancer stem cells: Opportunities and challenges.

Deciphering the "Rosetta Stone" of ovarian cancer stem cells: Opportunities and challenges.

Journal: Biochimica et biophysica acta. Reviews on cancer
Published: November 26, 2024

Transcription factor addictions: exploring the potential Achilles' Heel of endometriosis.

Transcription factor addictions: exploring the potential Achilles' Heel of endometriosis.

Journal: Science China. Life sciences
Published: September 24, 2024
Showing 1-12 of 94

Last Updated: 09/26/2026